Literature DB >> 10331736

Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB.

M E Kimerling1, H Kluge, N Vezhnina, T Iacovazzi, T Demeulenaere, F Portaels, F Matthys.   

Abstract

Multidrug-resistant tuberculosis (MDR-TB) threatens the progress of global control efforts. Prisons represent a high risk setting for development and transmission of MDR-TB. In a Siberian TB referral prison (Kemerovo region), the treatment failure rate is 35% (June 1996-March 1997), despite implementation of a strict DOTS program and use of the World Health Organization Category 2 re-treatment regimen for all new cases. Among 164 patients (December 1997-March 1998), initial resistance to isoniazid and rifampin is 22.6%. Such a rate is a warning call to reconsider prison control strategies, and importantly, to address the treatment regimens necessary to combat an institutional epidemic of MDR-TB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331736

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  16 in total

1.  Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital.

Authors:  V Goloubeva; M Lecocq; P Lassowsky; F Matthys; F Portaels; I Bastian
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Molecular genetic analysis of Mycobacterium tuberculosis strains spread in different patient groups in St. Petersburg, Russia.

Authors:  E Chernyaeva; P Dobrynin; N Pestova; N Matveeva; V Zhemkov; A Kozlov
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-08       Impact factor: 3.267

Review 3.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

4.  Pulmonary tuberculosis and drug resistance in Dhaka central jail, the largest prison in Bangladesh.

Authors:  Sayera Banu; Arman Hossain; Mohammad Khaja Mafij Uddin; Muhammad Reaj Uddin; Tahmeed Ahmed; Razia Khatun; Asif Mujtaba Mahmud; Khurshid Alam Hyder; Afzalunnessa Binte Lutfor; Md Sirajul Karim; Khalequ Zaman; Md Ashraful Islam Khan; Pravat Chandra Barua; Stephen P Luby
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

5.  Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis.

Authors:  Dalila Martínez; Gustavo Heudebert; Carlos Seas; German Henostroza; Martin Rodriguez; Carlos Zamudio; Robert M Centor; Cesar Herrera; Eduardo Gotuzzo; Carlos Estrada
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

6.  Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Authors:  Gustavo E Velásquez; Mercedes C Becerra; Irina Y Gelmanova; Alexander D Pasechnikov; Askar Yedilbayev; Sonya S Shin; Yevgeny G Andreev; Galina Yanova; Sidney S Atwood; Carole D Mitnick; Molly F Franke; Michael L Rich; Salmaan Keshavjee
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

7.  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Authors:  Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

8.  Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Authors:  Francine Matthys; Leen Rigouts; Vinciane Sizaire; Natalia Vezhnina; Maryvonne Lecoq; Vera Golubeva; Françoise Portaels; Patrick Van der Stuyft; Michael Kimerling
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

10.  Synthesis and biological evaluation of propargyl acetate derivatives as anti-mycobacterial agents.

Authors:  Parisa Azerang; Ali Hossein Rezayan; Soroush Sardari; Farzad Kobarfard; Mitra Bayat; Kimia Tabib
Journal:  Daru       Date:  2012-12-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.